In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci
about
RWJ-54428 (MC-02,479), a new cephalosporin with high affinity for penicillin-binding proteins, including PBP 2a, and stability to staphylococcal beta-lactamasesGlycosyltransferases and Transpeptidases/Penicillin-Binding Proteins: Valuable Targets for New AntibacterialsStructural Insights into the Anti-methicillin-resistant Staphylococcus aureus (MRSA) Activity of CeftobiproleCeftobiprole medocaril in the treatment of hospital-acquired pneumoniaPenicillin-binding proteins and beta-lactam resistanceCefepimeComparative study of the susceptibilities of major epidemic clones of methicillin-resistant Staphylococcus aureus to oxacillin and to the new broad-spectrum cephalosporin ceftobiprole.Newer antibacterial drugs for a new century.In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.Postgenomic strategies in antibacterial drug discovery.Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureusResistance and the management of complicated skin and skin structure infections: the role of ceftobiprole.Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010.The evolving role of chemical synthesis in antibacterial drug discovery.Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.Biological properties of novel antistaphylococcal quinoline-indole agents.Prodrugs of cephalosporin RWJ-333441 (MC-04,546) with improved aqueous solubilityEmerging agents to combat complicated and resistant infections: focus on ceftobiproleIn vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci.In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models.In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.Quality control guidelines for BAL9141 (Ro 63-9141), an investigational cephalosporin, when reference MIC and standardized disk diffusion susceptibility test methods are used.Cephalosporins in clinical development.Identification and phenotypic characterization of a beta-lactam-dependent, methicillin-resistant Staphylococcus aureus strainEfficacy of ceftobiprole Medocaril against Enterococcus faecalis in a murine urinary tract infection modelNew advances in antibiotic development and discovery.Investigational new drugs for the treatment of resistant pneumococcal infections.The antimicrobial armamentarium: evaluating current and future treatment options.Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.Treatment of Pseudomonas aeruginosa infection in critically ill patients.Cephalosporins for uncomplicated skin and skin structure infections in emerging community-acquired MRSA.Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strainsAnti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection modelsStructure-Activity Relationship for the 4(3H)-Quinazolinone AntibacterialsEfficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia.Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus
P2860
Q24554345-F3F30BAA-8E58-400A-A228-5AEF39D68504Q26749531-7E22A5EE-864B-4CD1-A5DE-70D25DB6DC9DQ27670836-310BFE1C-9A27-41C2-96BB-C6E623C21807Q28085517-BC0949B0-0A77-4254-B1A5-A466D79AD9EAQ28267300-0375E090-D76E-47F9-AD38-B59C8CD8F64CQ29040262-00F37CC2-128A-4AA1-B6CA-9BA262AAAA42Q30369604-1CC24960-2F55-475A-BAA3-8F95D4CC8D16Q30433333-806BE8CE-93A0-4588-A223-4CBD497F0A94Q33559139-7011E0C4-2309-4B04-8D24-45F1EFF4960CQ33745572-4E319D38-446A-4139-9D92-37692D9B339EQ33935282-79037262-200D-4EFE-BE46-79545A83598AQ34187667-C737A311-C4F9-4317-A67F-05FA2B472593Q34417616-A3CF8CEF-17DD-45EC-BE20-59F200A47A0AQ34427652-616740FD-9757-42F3-9C77-EB3FDC8809DDQ34433342-4E6C9C7C-EBEF-4820-88F2-5DC4F1E1B599Q34624359-91231FE0-FE05-4E32-B131-75CC1904EAC6Q34821242-FD39EB50-4FBB-429E-8219-688373F21507Q35014203-4D6F0E62-3AED-4080-8183-9D2ACBED37D0Q35026567-5E26538E-716F-4AC6-84AA-7B4BB5DB8CD1Q35124610-6DC1DDCA-88C5-43CE-8C7E-7699D2FF4FBAQ35166038-9B9404DA-41F2-4214-96F8-8B7D16B56D63Q35191417-597392E2-D430-49B8-AA5D-4F5C3D89E2CEQ35715050-96D4FF54-08CE-41B2-B5D9-A0A155CEF510Q35842532-7CBBE9F6-3036-4688-95CF-8B40A90897FAQ35879071-9B78C19D-66D1-47E2-ADDF-C1C3B9E533D3Q36018587-49208B2E-EB5E-4482-8058-00463900667EQ36065983-6A744C89-17C9-4420-B240-1B7AD5269AAEQ36210902-7B3EC9C5-97DA-40AF-BABF-120C09F06B1AQ36264494-CC62FDC3-2395-481E-8BAB-B3CEA2415468Q36422630-548CE9D4-8BE3-4919-A1E3-2186495126B7Q36607415-8A6C5B17-833E-4871-8386-1A00E6E716B3Q36613912-53E30903-2210-442A-BA3C-F58A19F15F00Q36744877-4FFF96F7-8ADD-46BA-A320-7E73F62E4513Q36763997-7A097310-8913-42FC-AA9D-7B1E5C9D4ECCQ36804049-8B474022-E89F-4E9E-8415-BBBE4E802710Q36932924-98CE9A5D-1BB9-499E-8DE9-CCA1567C7D94Q36947075-F1D57616-F0EE-4CD6-B7D5-E227C354CEF6Q37119259-3DA85153-4DF3-4BD0-B127-4E5D846E30FEQ37162872-03E239F6-308D-4B78-972C-D35DDFCAA460Q37204106-C8A87909-CB9A-485E-8E40-45B323514B07
P2860
In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
In vitro and in vivo propertie ...... cillin-resistant staphylococci
@ast
In vitro and in vivo propertie ...... cillin-resistant staphylococci
@en
In vitro and in vivo propertie ...... cillin-resistant staphylococci
@nl
type
label
In vitro and in vivo propertie ...... cillin-resistant staphylococci
@ast
In vitro and in vivo propertie ...... cillin-resistant staphylococci
@en
In vitro and in vivo propertie ...... cillin-resistant staphylococci
@nl
prefLabel
In vitro and in vivo propertie ...... cillin-resistant staphylococci
@ast
In vitro and in vivo propertie ...... cillin-resistant staphylococci
@en
In vitro and in vivo propertie ...... cillin-resistant staphylococci
@nl
P2093
P2860
P3181
P1476
In vitro and in vivo propertie ...... cillin-resistant staphylococci
@en
P2093
P2860
P304
P3181
P356
10.1128/AAC.45.3.825-836.2001
P407
P577
2001-03-01T00:00:00Z